A Paradoxical Treatment for a Paradoxical Condition: Infliximab Use in Three Cases of Mycobacterial IRIS | Zendy

Denise C. Hsu | Zendy; Kimberly F. Faldetta | Zendy; Luxin Pei | Zendy; Virginia Sheikh | Zendy; Netanya S. Utay | Zendy; Gregg Roby | Zendy; Adam Rupert | Zendy; Anthony S. Fauci | Zendy; Irini Sereti | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A Paradoxical Treatment for a Paradoxical Condition: Infliximab Use in Three Cases of Mycobacterial IRIS

Author(s) -

Denise C. Hsu,

Kimberly F. Faldetta,

Luxin Pei,

Virginia Sheikh,

Netanya S. Utay,

Gregg Roby,

Adam Rupert,

Anthony S. Fauci,

Irini Sereti

Publication year - 2015

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/civ841

Subject(s) - immune reconstitution inflammatory syndrome , medicine , infliximab , iris (biosensor) , adverse effect , paradoxical reaction , refractory (planetary science) , immunology , clinical trial , blockade , tumor necrosis factor alpha , antiretroviral therapy , dermatology , human immunodeficiency virus (hiv) , pathology , viral load , tuberculosis , physics , computer security , astrobiology , computer science , biometrics , receptor

The management of corticosteroid refractory immune reconstitution inflammatory syndrome (IRIS) is currently unclear. Infliximab administration was associated with clinical improvement without significant adverse events in 3 patients with mycobacterial IRIS. Immunologic and virologic responses to antiretroviral therapy were unaffected. Tumor necrosis factor blockade may be beneficial for IRIS and warrants further study in clinical trials.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research